



## Forced Labour and Child Labour Report 2025 Aurinia Pharmaceuticals Inc.

This Forced Labour and Child Labour Report (the “**Report**”) addresses the period from January 1, 2025 to December 31, 2025 (“**FY2025**”) and has been prepared in compliance with the *Fighting Against Forced Labour and Child Labour in Supply Chains Act* (Canada) (the “**Act**”). This Report is made on behalf of Aurinia Pharmaceuticals Inc. (“**Aurinia**”).

### 1. Introduction

This Report sets out the actions Aurinia has taken during Fiscal Year 2025 to prevent and reduce the risk that forced labour or child labour is used at any step in the production of goods by Aurinia. Aurinia does not produce or manufacture goods in Canada.

### 2. Our Structure, Activities and Supply Chain

Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, Aurinia introduced LUPKYNIS<sup>®</sup> (voclosporin), the first U.S. Food and Drug Administration (“**FDA**”)-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.

In December 2020, Aurinia entered into a collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd., (“**Otsuka**”) to develop and commercialize oral voclosporin in Japan, the European Union, the United Kingdom, Switzerland, Russia, Norway, Belarus, Iceland, Liechtenstein and Ukraine. Otsuka has obtained regulatory approval of LUPKYNIS in Japan, the European Union, the United Kingdom and Switzerland.

Aurinia's head and registered office is located at #140, 14315-118 Avenue, Edmonton, Alberta, Canada T5L 4S6. Aurinia's U.S. commercial office is located at 77 Upper Rock Circle, Suite 700, Rockville, Maryland, 20850, United States.

Aurinia is formed pursuant to the *Business Corporations Act* (Alberta). The Company's common shares are traded on the Nasdaq Global Market under the symbol AUPH.

Aurinia's FY2025 supply chain included contract manufacturing organizations (“**CMOs**”). Aurinia uses a CMO in Switzerland to manufacture active pharmaceutical ingredient, and CMOs in the United States to complete drug product manufacturing and packaging into finished goods. Aurinia's CMO sites are in countries which are not considered high-risk jurisdictions by the Global Slavery Index.

### 3. Our Policies and Due Diligence

#### Policies

Through our organizational and governance policies, Aurinia communicates its values and expectations, for itself, its suppliers, and its selling partners.



### **Code of Ethics and Conduct**

Aurinia is committed to conducting its business in a lawful and ethical manner. Aurinia's Code of Ethics and Conduct (the "Code") is the foundation of its corporate policies and sets out guiding principles on professional conduct, including that Aurinia's directors and employees should always act lawfully, ethically and in the best interests of Aurinia.

### **Whistleblower Policy**

In accordance with Aurinia's Whistleblower Policy, it is the responsibility of all of Aurinia's directors and employees to comply with the Code and to report actual or suspected misconduct, illegal activities or fraud. Aurinia provides several methods of reporting misconduct including to an employee's manager, Aurinia's Chief Compliance Officer, Aurinia's Legal Department or an independent and anonymous hotline managed by a third-party and available 24 hours a day, 7 days a week.

### **Due Diligence**

Aurinia acknowledges that employees working in its offices and in the facilities of the entities in its supply chain are at potential risk of being the subjects of forced or child labour. Aurinia expects all third parties (including Aurinia's suppliers described in section 2 of this Report) with which it works to adhere to business principles and values similar to its own and to comply with all applicable laws and regulations. As part of its contracting process, Aurinia requires all of its vendors to provide representations and warranties that the vendor does not engage in forced and child labour practices. Aurinia and the FDA have conducted various audits at Aurinia's suppliers that, to Aurinia's knowledge, revealed no instances of forced or child labour.

#### **4. Assessing Our Risk**

Due to the nature of its business, Aurinia and its suppliers are heavily regulated, and subject to significant regulatory oversight. Aurinia follows all applicable regulations and laws. Although Aurinia's exposure to the risk of forced or child labour increases when it engages with third party vendors, that risk is mitigated by the heavy regulations and oversight that the pharmaceutical industry places on participants and through Aurinia's own policies, procedures and due diligence.

Aurinia assesses the risk of exposure to forced and child labour in its business and supply chain as low.

#### **5. Our Commitments**

Aurinia's Code and Whistleblower Policy require all directors and employees to report actual or possible misconduct. Aurinia also undertakes diligence efforts (as further described in this Report) to ensure that the risk of forced labour and child labour is mitigated in its business. Aurinia's hiring practices ensure that it hires age-appropriate labour.

While no reports or complaints regarding forced labour or child labour regarding Aurinia's or, to Aurinia's knowledge, Aurinia's suppliers have been received at the time of filing this Report, should such circumstances arise, Aurinia is dedicated to upholding its commitments to combat these issues while actively working to mitigate any resulting adverse impacts, including financial, on Aurinia and its operations. As Aurinia has not identified any instances of forced or child labour in its supply chain, there



were no measures needed for Aurinia to remediate forced or child labour or to remediate the loss of income to the most vulnerable families arising from forced or child labour.

At least annually, Aurinia personnel are required to complete a training regimen. Although Aurinia's employee training does not include dedicated training on forced and child labour, every employee must complete training on Aurinia's values and policies, including the Code, and is informed of how to report wrongdoing under the Whistleblower Policy.

## **6. Our Progress and Effectiveness**

As part of Aurinia's governance processes, Aurinia monitors employees' compliance with training on its policies on an ongoing basis. Aurinia also reviews any concerns raised through its Whistleblower Policy and other informal mechanisms of employee feedback. To date no significant concerns or complaints related to forced or child labour have been identified.

Aurinia has prioritized building foundational measures to address the risks of forced labour and child labour in its operations and supply chains, such as updating its master service agreements, requests for proposals, service agreements, consultancy agreements and other vendor contracts to include representations and warranties that none of its vendors utilize any forced or child labour in the provision of services to Aurinia. However, the development of formalized policies and procedures for evaluating the effectiveness of these measures has not yet been completed. Aurinia continues to aim to keep its policies and procedures under review and to explore additional steps for assessing their effectiveness in future years.

### **Approval & Signature**

In accordance with paragraph 11(4)(a) of the Act, this Report was approved by Aurinia's Board of Directors and has been submitted to the Minister of Public Safety and Emergency Preparedness in Canada. This Report is also available on Aurinia's company website at [www.auriniapharma.com](http://www.auriniapharma.com) and on Aurinia's profile on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca).

In accordance with the requirements of the Act, and in particular section 11 thereof, I attest that I have reviewed the information contained in this Report for the entity listed above. Based on my knowledge, and having exercised reasonable diligence, I attest that the information in this Report is true, accurate and complete in all material respects for the purposes of the Act, for the reporting year listed above.

Signed and approved this 31<sup>st</sup> day of May, 2026.

/s/ Kevin Tang

Name: Kevin Tang

Title: Chief Executive Officer and  
Chair of the Board of Directors

I have the authority to bind Aurinia.